Full 4-pillar GDMT (ARNi + evidence-based beta-blocker + MRA + SGLT2i) simultaneously-initiated and titrated to target dose or maximally-tolerated dose over 4–8 weeks.
Authored pathway active · heart-failure-with-reduced-ejection-fraction.outpatient
Full 4-pillar GDMT (ARNi + evidence-based beta-blocker + MRA + SGLT2i) simultaneously-initiated and titrated to target dose or maximally-tolerated dose over 4–8 weeks.
Guidelines: ACC/AHA/HFSA 2022 HF Guideline + 2023 Focused Update · ESC 2021 HF Guideline · PARADIGM-HF, DAPA-HF, EMPEROR-Reduced, EMPHASIS-HF
Phenotypes (4)
- HFrEF — Newly Diagnosed (LVEF ≤40%, Initiation of GDMT)
- HFrEF — Optimized on 4-Pillar GDMT (Stable Ambulatory)
- Advanced HFrEF — Refractory (NYHA IV Despite Optimal GDMT)
- HFrEF with Iron Deficiency (Ferritin <100 or TSAT <20%)
Pathway-scoped symptom and exam intake
Test this pathway's ROS and differential links
Uses LR engine cardio.hfref.core.v1, then routes suggested engines into the workspace.
19-panel workspace
heart-failure-with-reduced-ejection-fraction · OutpatientStart patient workup
Open a scratch or linked encounter, add active problems, then keep labs, fluids, acid-base, and electrolyte tools beside the main workspace instead of losing context.
Encounter and problems
No encounter open. Add a problem to create a scratch encounter when none is open.
Multi-window tools
Unified
labs + fluids + acid-base
Labs
fast lab analyzer
Fluid
resuscitation and balance
Electrolytes
Na/K/Mg/Phos/Ca
ABG/VBG
compensation and mixed disorders
Popular entry points
6 quick-startsOr jump straight to the atlas
The Engine Atlas covers every authored disease package with setting chips and pathway badges. Open any engine to load its 19-panel workspace, backed by phenotype-aware reasoning and monitored by the Flow Assistant.